Sign In
Section Navigation
Common TitleSTRIIVING
Official Title A Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Phase Phase IIIB
ClinicalTrials.gov NCT02105987
Treatments
Dolutegravir-Abacavir-Lamivudine
Dolutegravir-Abacavir-Lamivudine Triumeq

Dolutegravir-Abacavir-Lamivudine

Tradename:TriumeqOther Names:DTG-ABC-3TCClass:Single-Tablet Regimens
Categories Treatment-ExperiencedSwitch/Simplification
Funding
IndustryViiV Healthcare
References
  • Trottier B, Lake JE, Logue K, et al. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study. Antivir Ther. 2017;22:295-305.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.